Peapack Gladstone Financial Corp Lowers Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Peapack Gladstone Financial Corp trimmed its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 27.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 11,267 shares of the company’s stock after selling 4,176 shares during the quarter. Peapack Gladstone Financial Corp’s holdings in Teva Pharmaceutical Industries were worth $203,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. FMR LLC boosted its holdings in Teva Pharmaceutical Industries by 49.5% during the third quarter. FMR LLC now owns 62,740,763 shares of the company’s stock worth $1,130,589,000 after purchasing an additional 20,762,226 shares during the last quarter. Janus Henderson Group PLC boosted its stake in shares of Teva Pharmaceutical Industries by 7,945.2% in the 3rd quarter. Janus Henderson Group PLC now owns 4,791,937 shares of the company’s stock worth $86,350,000 after buying an additional 4,732,374 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Teva Pharmaceutical Industries by 237.5% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,377,517 shares of the company’s stock valued at $60,863,000 after acquiring an additional 2,376,668 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd increased its position in shares of Teva Pharmaceutical Industries by 6.8% during the third quarter. Clal Insurance Enterprises Holdings Ltd now owns 34,543,812 shares of the company’s stock valued at $621,337,000 after acquiring an additional 2,204,623 shares during the last quarter. Finally, State Street Corp lifted its holdings in Teva Pharmaceutical Industries by 10.0% during the third quarter. State Street Corp now owns 19,500,683 shares of the company’s stock worth $351,402,000 after acquiring an additional 1,778,268 shares during the period. Institutional investors own 54.05% of the company’s stock.

Insider Activity at Teva Pharmaceutical Industries

In other news, EVP Christine Fox sold 19,388 shares of Teva Pharmaceutical Industries stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total transaction of $327,075.56. Following the completion of the sale, the executive vice president now owns 44,104 shares in the company, valued at approximately $744,034.48. This trade represents a 30.54 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.55% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

TEVA has been the subject of several research analyst reports. StockNews.com raised Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. UBS Group lifted their price objective on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. Barclays increased their target price on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the company an “overweight” rating in a research report on Wednesday, October 23rd. Finally, JPMorgan Chase & Co. upped their price objective on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a research note on Monday, October 21st. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $19.67.

Teva Pharmaceutical Industries Price Performance

Shares of NYSE TEVA opened at $16.50 on Tuesday. The company has a quick ratio of 0.61, a current ratio of 0.89 and a debt-to-equity ratio of 2.57. The company has a market cap of $18.69 billion, a P/E ratio of -19.41, a P/E/G ratio of 0.99 and a beta of 0.79. Teva Pharmaceutical Industries Limited has a 52 week low of $10.00 and a 52 week high of $19.31. The business has a 50-day simple moving average of $17.49 and a two-hundred day simple moving average of $17.40.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.